Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Weight Management in Duchenne Muscular Dystrophy
NCT07642635Phase 2Not yet recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in obesity, Overweight, sponsored by Vanderbilt University Medical Center. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07642635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07642635.